64 related articles for article (PubMed ID: 30957411)
21. The Role of Endoglin in Hepatocellular Carcinoma.
Jeng KS; Sheen IS; Lin SS; Leu CM; Chang CF
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809908
[TBL] [Abstract][Full Text] [Related]
22. EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.
Gu F; Yuan S; Liu L; Zhu P; Yang Y; Pan Z; Zhou W
J Cell Mol Med; 2019 Jun; 23(6):4208-4216. PubMed ID: 30957411
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
24. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
Chen P; Duan X; Li X; Li J; Ba Q; Wang H
Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
[TBL] [Abstract][Full Text] [Related]
25. EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552.
Zhu XX; Li JH; Cai JP; Hou X; Huang CS; Huang XT; Wang JQ; Li SJ; Xu QC; Yin XY
Cancer Sci; 2019 Oct; 110(10):3110-3121. PubMed ID: 31385398
[TBL] [Abstract][Full Text] [Related]
26. miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop.
Zhang F; Li K; Pan M; Li W; Wu J; Li M; Zhao L; Wang H
J Exp Clin Cancer Res; 2018 Jul; 37(1):152. PubMed ID: 30012200
[TBL] [Abstract][Full Text] [Related]
27. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
[TBL] [Abstract][Full Text] [Related]
28. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer.
Zhao J; Du P; Cui P; Qin Y; Hu C; Wu J; Zhou Z; Zhang W; Qin L; Huang G
Oncogene; 2018 Jul; 37(30):4094-4109. PubMed ID: 29706652
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
[TBL] [Abstract][Full Text] [Related]
30. Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
Liu TY; Chen J; Shang CL; Shen HW; Huang JM; Liang YC; Wang W; Zhao YH; Liu D; Shu M; Guo LY; Hu Z; Yao SZ
J Exp Clin Cancer Res; 2016 Oct; 35(1):170. PubMed ID: 27793172
[TBL] [Abstract][Full Text] [Related]
31. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
32. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
[TBL] [Abstract][Full Text] [Related]
33. EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer.
Kim SJ; Tae CH; Hong SN; Min BH; Chang DK; Rhee PL; Kim JJ; Kim HC; Kim DH; Kim YH
Mol Carcinog; 2015 Dec; 54(12):1748-57. PubMed ID: 25620232
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
[TBL] [Abstract][Full Text] [Related]
35. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.
Wilson IM; Vucic EA; Enfield KS; Thu KL; Zhang YA; Chari R; Lockwood WW; Radulovich N; Starczynowski DT; Banáth JP; Zhang M; Pusic A; Fuller M; Lonergan KM; Rowbotham D; Yee J; English JC; Buys TP; Selamat SA; Laird-Offringa IA; Liu P; Anderson M; You M; Tsao MS; Brown CJ; Bennewith KL; MacAulay CE; Karsan A; Gazdar AF; Lam S; Lam WL
Oncogene; 2014 Sep; 33(36):4464-73. PubMed ID: 24096489
[TBL] [Abstract][Full Text] [Related]
36. The Eyes Absent proteins in development and disease.
Tadjuidje E; Hegde RS
Cell Mol Life Sci; 2013 Jun; 70(11):1897-913. PubMed ID: 22971774
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.
Miller SJ; Lan ZD; Hardiman A; Wu J; Kordich JJ; Patmore DM; Hegde RS; Cripe TP; Cancelas JA; Collins MH; Ratner N
Oncogene; 2010 Jan; 29(3):368-79. PubMed ID: 19901965
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the innate immune response by threonine-phosphatase of Eyes absent.
Okabe Y; Sano T; Nagata S
Nature; 2009 Jul; 460(7254):520-4. PubMed ID: 19561593
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
